In breast cancer, FOXA1-driven enhancer reprogramming has been shown to activate HIF2α via super-enhancer engagement, thereby linking FOXA1 to hypoxia-associated oncogenic programs [23]. This evidence concerns the gene FOXA1 and breast cancer.